Literature DB >> 31444625

Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change.

Sho Tsuyama1, Tsuyoshi Saito2,3, Yoichi Akazawa1,4, Yuka Yanai1, Noboru Yatagai1,4, Keisuke Akaike5, Takuo Hayashi1, Yoshiyuki Suehara6,5, Fumiyuki Takahashi6,7, Kazuya Takamochi8, Takashi Hashimoto9, Yoshiaki Kajiyama9, Masahiko Tsurumaru9, Tetsu Fukunaga10, Takashi Yao1.   

Abstract

The molecular pathogenesis of esophageal carcinosarcoma (ECS) has not been fully investigated. This study includes 16 consequent cases of surgically resected ECS. Genetic alterations were independently examined for carcinoma in situ, carcinomatous, and sarcomatous areas. Six cases were analyzed by next-generation sequencing, and the remaining cases were analyzed by Sanger sequencing for TP53, PTEN, and INI1. Sarcomatous components in 3 cases showed histologically heterogenous feature of osteosarcoma. Lymph node metastasis was found in 12 out of 16 cases. Survival analysis revealed 5-year overall survival rate of 59.9%, and the median survival time was 5.37 years. TP53 was the most frequently mutated gene, being identified in 11 of 16 patients (68.8%), 7 of whom (63.6%) had the same mutations in both carcinomatous and sarcomatous areas. Almost complete concordance was found between p53 immunohistochemistry and TP53 missense mutations. Five-year overall survival tended to be worse for patients with p53 overexpression, although the data was not significant (p = 0.186). Nine of 16 patients (56.3%) showed loss of heterozygosity (LOH) at the INI1 locus, and this LOH status was consistent with both components. However, interestingly, INI1 expression was preserved in all cases. In addition, copy number variation analysis revealed gene amplification in several tyrosine kinase receptors. Accumulation of mutations in tumor suppressor genes such as TP53 and INI1 seemed to occur during ECS development.

Entities:  

Keywords:  Esophageal carcinosarcoma; INI1; LOH; Next-generation sequencing; TP53; Tumorigenesis

Mesh:

Substances:

Year:  2019        PMID: 31444625     DOI: 10.1007/s00428-019-02643-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Polypoid carcinoma of the esophagus. A unifying term for "carcinosarcoma" and "pseudosarcoma".

Authors:  R Y Osamura; K Shimamura; J Hata; N Tamaoki; K Watanabe; M Kubota; S Yamazaki; T Mitomi
Journal:  Am J Surg Pathol       Date:  1978-06       Impact factor: 6.394

2.  Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.

Authors:  Qianming Bai; Xin Zhang; Xiaoli Zhu; Lei Wang; Dan Huang; Xu Cai; Xiaoyan Zhou; Jian Wang; Weiqi Sheng
Journal:  Histopathology       Date:  2016-05-24       Impact factor: 5.087

3.  Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma.

Authors:  Akihiko Sano; Shinji Sakurai; Hiroyuki Kato; Makoto Sakai; Naritaka Tanaka; Takanori Inose; Kana Saito; Makoto Sohda; Masanobu Nakajima; Kazuha Sakamoto; Takaaki Sano; Yoshinori Hosoya; Takehiko Enomoto; Tatsuo Kanda; Yoichi Ajioka; Tetsunari Oyama; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

4.  SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.

Authors:  Abbas Agaimy; Arndt Hartmann; Cristina R Antonescu; Simion I Chiosea; Samir K El-Mofty; Helene Geddert; Heinrich Iro; James S Lewis; Bruno Märkl; Stacey E Mills; Marc-Oliver Riener; Thomas Robertson; Ann Sandison; Sabine Semrau; Roderick H W Simpson; Edward Stelow; William H Westra; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

5.  SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns.

Authors:  Aanchal Kakkar; Vijay Mariadas Antony; Raja Pramanik; Pirabu Sakthivel; Chirom Amit Singh; Deepali Jain
Journal:  Hum Pathol       Date:  2018-08-16       Impact factor: 3.466

Review 6.  Uterine carcinosarcoma: A review of the literature.

Authors:  Leigh A Cantrell; Stephanie V Blank; Linda R Duska
Journal:  Gynecol Oncol       Date:  2015-03-21       Impact factor: 5.482

7.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Authors:  Magali Olivier; Anita Langerød; Patrizia Carrieri; Jonas Bergh; Sigrid Klaar; Jorunn Eyfjord; Charles Theillet; Carmen Rodriguez; Rosette Lidereau; Ivan Bièche; Jennifer Varley; Yves Bignon; Nancy Uhrhammer; Robert Winqvist; Arja Jukkola-Vuorinen; Dieter Niederacher; Shunsuke Kato; Chikashi Ishioka; Pierre Hainaut; Anne-Lise Børresen-Dale
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

8.  Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.

Authors:  Brian David Lehmann; Yan Ding; Daniel Joseph Viox; Ming Jiang; Yi Zheng; Wang Liao; Xi Chen; Wei Xiang; Yajun Yi
Journal:  BMC Cancer       Date:  2015-03-26       Impact factor: 4.430

9.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

10.  Comprehensive Registry of Esophageal Cancer in Japan, 2010.

Authors:  Yuji Tachimori; Soji Ozawa; Hodaka Numasaki; Ryu Ishihara; Hisahiro Matsubara; Kei Muro; Tsuneo Oyama; Yasushi Toh; Harushi Udagawa; Takashi Uno
Journal:  Esophagus       Date:  2017-05-19       Impact factor: 4.230

View more
  1 in total

1.  Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma.

Authors:  Michał Kunc; Anna Gabrych; Bartłomiej Rękawiecki; Adam Gorczyński; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2020-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.